Prostate Cancer

A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes.

Reuters reports on a study published in European Urology that shows that black men in America with medium- and high-risk prostate tumors are less likely to get aggressive treatment than white men are.

In a new study, researchers used a patient's own cancer history rather than family history to identify genetic mutations that might influence cancer treatment and risk for family members.

New, statistically derived guidelines are helping urologists across Michigan zero in on which prostate cancer patients to scan for spread of their disease.

When small-molecule inhibitors proved elusive, researchers developed a novel strategy: Using large molecule peptides to target a common prostate cancer driver. It may provide a path for developing new therapies against a challenging target.

It’s well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations – along with a handful of others – and aggressive prostate cancer.